<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9765">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05690698</url>
  </required_header>
  <id_info>
    <org_study_id>QHMHD</org_study_id>
    <nct_id>NCT05690698</nct_id>
  </id_info>
  <brief_title>Quetiapine Versus Haloperidol in the Management of Hyperactive Delirium; Randomized Study</brief_title>
  <official_title>Quetiapine Versus Haloperidol in the Management of Hyperactive Delirium; Randomized Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In population of intensive care unit (ICU), most studies compared atypical antipsychotics&#xD;
      such as quetiapine with the traditional haloperidol in delirious patients of various forms&#xD;
      and etiologies. The role of such agents in patients with hyperactive is not fully understood.&#xD;
&#xD;
      This study compares the effectiveness of quetiapine with haloperidol in treating the&#xD;
      hyperactive form of delirium in terms of their effects on morbidity, length of stay in the&#xD;
      intensive care unit, and mortality in critically ill patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A common complication in the intensive care unit (ICU) that has recently been identified is&#xD;
      delirium. Defining delirium as a &quot;sudden deterioration in attention, awareness, and&#xD;
      cognition, which is not explained by any pre-existing neurocognitive disorder, but because of&#xD;
      another medical condition,&quot; the Diagnostic and Statistical Manual of Mental Disorders (DSM-V)&#xD;
      clarified the definition of delirium.&#xD;
&#xD;
      A dibenzothiazepine derivative with a novel and distinctive pharmacologic profile is&#xD;
      quetiapine. The limbic system is overactive in delirium, which is one of its&#xD;
      pathophysiologies. By obstructing the mesolimbic dopamine D2 receptors specifically,&#xD;
      quetiapine may be able to regulate this hyperactivity.&#xD;
&#xD;
      The objective of this study is to compare the effectiveness of quetiapine with haloperidol in&#xD;
      treating the hyperactive form of delirium in terms of their effects on morbidity, length of&#xD;
      stay in ICU, and mortality in critically ill patients.&#xD;
&#xD;
      This research will not receive any grants, funding, or financial aid (NOT FUNDED STUDY).&#xD;
      Collaborators declare that they have no conflicts of interest.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">April 9, 2023</start_date>
  <completion_date type="Anticipated">January 15, 2024</completion_date>
  <primary_completion_date type="Anticipated">January 15, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Parallel random assignment to receive either oral quetiapine (25-50 mg/day) or haloperidol (1-2 mg/day)</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Double blinded trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Day 7</time_frame>
    <description>Response rate is defined as a reduction of the DRS-R-98 severity score from its baseline for 50% or more and a DRS-R-98 severity score of 12 or less without relapse</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>week 6 from enrollment</time_frame>
    <description>In-hospital all cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU-mortality</measure>
    <time_frame>week 6 from enrollment</time_frame>
    <description>ICU all cause mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for MV</measure>
    <time_frame>week 6 from enrollment</time_frame>
    <description>Need for mechanical ventilation during ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU stay</measure>
    <time_frame>week 6 from enrollment</time_frame>
    <description>Number of days of ICU stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital stay</measure>
    <time_frame>week 6 from enrollment</time_frame>
    <description>Number of days of hospital stay</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Sleeping hours</measure>
    <time_frame>Day 3</time_frame>
    <description>Sleeping hours per night</description>
  </other_outcome>
  <other_outcome>
    <measure>Sleeping hours</measure>
    <time_frame>Day 7</time_frame>
    <description>Sleeping hours per night</description>
  </other_outcome>
  <other_outcome>
    <measure>Delirium Rating Scale-revised-98 severity score</measure>
    <time_frame>Day 3</time_frame>
    <description>The DRS-R-98 is a valid measure of delirium severity over a broad range of symptoms and is a useful diagnostic and assessment tool, maximum severity score of 39 points</description>
  </other_outcome>
  <other_outcome>
    <measure>Delirium Rating Scale-revised-98 severity score</measure>
    <time_frame>Day 7</time_frame>
    <description>The DRS-R-98 is a valid measure of delirium severity over a broad range of symptoms and is a useful diagnostic and assessment tool, maximum severity score of 39 points</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Hyperactive Delirium</condition>
  <arm_group>
    <arm_group_label>Quatiapine group (n=50)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Quetiapine (25-50 mg/day) according to their symptoms of agitations.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Haloperidol group (n=50)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Haloperidol (1-2 mg/day) according to their symptoms of agitations.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Quatiapine</intervention_name>
    <description>Atypical antipsychotic</description>
    <arm_group_label>Quatiapine group (n=50)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol</intervention_name>
    <description>Antipsychotic</description>
    <arm_group_label>Haloperidol group (n=50)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All patients who are diagnosed with hyperactive form of delirium during their ICU stay&#xD;
             using CAM-ICU tool (the confusion assessment method for the intensive care unit)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Suspected substance-induced delirium&#xD;
&#xD;
          -  Previous use of antipsychotics&#xD;
&#xD;
          -  Known allergy or intolerance to the study drugs&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
&#xD;
          -  Acute renal injury&#xD;
&#xD;
          -  Hepatic failure&#xD;
&#xD;
          -  Inability to tolerate oral drugs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tamer N. Habib, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Alexandria</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Islam E. Ahmed, PharmD</last_name>
    <role>Study Chair</role>
    <affiliation>Faculty of Medicine, Suez-canal University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ibrahim K. Luttfi, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Faculty of Medicine, Gezira University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine, Alexandria University Hospitals</name>
      <address>
        <city>Alexandria</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>December 28, 2022</study_first_submitted>
  <study_first_submitted_qc>January 17, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 19, 2023</study_first_posted>
  <last_update_submitted>April 9, 2023</last_update_submitted>
  <last_update_submitted_qc>April 9, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 11, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Critical Care</keyword>
  <keyword>Hyperactive Delirium</keyword>
  <keyword>antipsychotics</keyword>
  <keyword>Haloperidol</keyword>
  <keyword>Quetiapine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Delirium</mesh_term>
    <mesh_term>Hyperkinesis</mesh_term>
    <mesh_term>Psychomotor Agitation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

